UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Medline ® Abstract for Reference 71

of 'Management of patients at high risk for breast and ovarian cancer'

71
TI
Population-based study of contralateral prophylactic mastectomy and survival outcomes of breast cancer patients.
AU
Bedrosian I, Hu CY, Chang GJ
SO
J Natl Cancer Inst. 2010;102(6):401. Epub 2010 Feb 25.
 
BACKGROUND: Despite increased demand for contralateral prophylactic mastectomy (CPM), the survival benefit of this procedure remains uncertain.
METHODS: We used the Surveillance, Epidemiology, and End Results database to identify 107 106 women with breast cancer who had undergone mastectomy for treatment between 1998 and 2003 and a subset of 8902 women who also underwent CPM during the same period. Associations between predictor variables and the likelihood of undergoing CPM were evaluated by use of chi(2) analyses. Risk-stratified (estrogen receptor [ER]status, stage, and age) adjusted survival analyses were performed by using Cox regression. Statistical tests were two-sided.
RESULTS: In a univariate analysis, CPM was associated with improved disease-specific survival (hazard ratio [HR]of death = 0.63, 95% confidence interval [CI]= 0.57 to 0.69; P<.001). Risk-stratified analysis showed that this association was because of a reduction in breast cancer-specific mortality in women aged 18-49 years with stages I-II ER-negative cancer (HR of death = 0.68, 95% CI = 0.53to 0.88; P = .004). Five year-adjusted breast cancer survival for this group was improved with CPM vs without (88.5% vs 83.7%, difference = 4.8%). Although rates of contralateral breast cancer among young women with stages I-II disease undergoing CPM were independent of ER status, women with ER-positive tumors in the absence of prophylactic mastectomy also had a lower overall risk for contralateral breast cancer than women with ER-negative tumors (0.46% vs 0.90%, difference = 0.44%; P<.001).
CONCLUSIONS: CPM is associated with a small improvement in 5-year breast cancer-specific survival mainly in young women with early-stage ER-negative breast cancer. This effect is related to a higher baseline risk of contralateral breast cancer.
AD
Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX , USA. ibedrosian@mdanderson.org
PMID